Division of Haematology, School of Cancer Studies, University of Liverpool, Liverpool, United Kingdom.
Blood. 2010 Jun 3;115(22):4447-54. doi: 10.1182/blood-2009-06-229872. Epub 2010 Feb 17.
Chronic lymphocytic leukemia (CLL) is a malignant disease of mature B lymphocytes. We have previously shown that a characteristic feature of CLL cells are high levels of expression and activity of protein kinase CbetaII (PKCbetaII), and that this might influence disease progression by modulating signaling in response to B-cell receptor engagement. The aim of the present work was to investigate the factors involved in stimulating PKCbetaII expression in CLL cells. Here we show that the activation of PKCbetaII in CLL cells stimulated with vascular endothelial growth factor (VEGF) can drive expression of the gene for PKCbeta, PRKCB1. We found that this effect of VEGF on PRKCB1 transcription is paralleled by high expression of PKCbetaII protein and therefore probably contributes to the malignant phenotype of CLL cells. Taken together, the data presented in this study demonstrate that VEGF, in addition to its role in providing prosurvival signals, also plays a role in overexpression of PKCbetaII, an enzyme with a specific pathophysiologic role in CLL.
慢性淋巴细胞白血病(CLL)是一种成熟 B 淋巴细胞的恶性疾病。我们之前已经表明,CLL 细胞的一个特征是蛋白激酶 CβII(PKCβII)的高表达和高活性,这可能通过调节 B 细胞受体结合后的信号转导来影响疾病的进展。本研究的目的是探讨刺激 CLL 细胞中 PKCβII 表达的相关因素。在这里,我们发现血管内皮生长因子(VEGF)刺激 CLL 细胞中 PKCβII 的激活可以驱动 PKCβ 基因(PRKCB1)的表达。我们发现 VEGF 对 PRKCB1 转录的这种作用与 PKCβII 蛋白的高表达平行,因此可能有助于 CLL 细胞的恶性表型。总之,本研究中的数据表明,VEGF 除了在提供生存信号方面的作用外,还在 PKCβII 的过度表达中发挥作用,PKCβII 是 CLL 中具有特定病理生理作用的一种酶。